Fresenius Group Overview

February 24, 2021

Fresenius wins tenth consecutive Potentialpark award for Germany’s best online offering for job applicants

  • The market research institute Potentialpark has honored the global healthcare group Fresenius as the German company with the best overall Internet offering for job applicants.

    Download Image (PNG 918 KB)
Download image

The market research institute Potentialpark has honored the global healthcare group Fresenius for the tenth consecutive year as the German company with the best overall Internet offering for job applicants.

In Potentialpark’s 2021 study, Fresenius not only took first place in the overall category for all career-relevant online activities, but also won in the individual category of career assessment in social media. Fresenius finished second in the online application management and mobile offering category, and third for career website.

Potentialpark has carried out an annual study of German companies’ online offerings for job applicants since 2002. For this year’s study, Potentialpark assessed the online activities of 121 companies in Germany according to more than 300 criteria. More than 53,000 students and graduates around the world were surveyed about their preferences.

”Communication with job applicants has moved even more strongly into the virtual domain since the start of the coronavirus pandemic,” said Michael Lehmann, Senior Vice President Corporate Human Resources of Fresenius. “Hardly any in-person meetings can take place currently for job interviews or at job and trade fairs. It is therefore even more important for us to make up for this loss through online communications, and to reach new talent through exciting digital formats. Because even during the pandemic, we are continuing to hire new employees.”

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.